Tag Archive for: psilocybin
Psychedelic Business Spotlight – December 24
Business, Stock ReportsThis week in psychedelic business news: FDA green lights a new psilocybin study; MindMed commences LSD treatment for ADHD; Sage Institute shuffles leadership.
FDA Green Lights Tryp Therapeutics’ Psilocybin Study on Binge Eating Disorder
ResearchThe pharmaceutical company developing psilocybin-based compounds for diseases with unmet medical needs estimates a $2.9 billion market potential for such a treatment.
A Second Washington City Approves Decriminalizing Psychedelics
PolicyThe psychedelic movement keeps on moving in the Pacific Northwest following Seattle's decriminalization resolution passing earlier this year.
Australia Rejects Bid to Reschedule Psilocybin, MDMA for Therapeutic Use
PolicyMind Medicine Australia, a psychedelics advocacy organization that filed the application, says the country "lost a massive opportunity to be a leader in this field with this decision.”
New York Legislator Introduces Bill to Legalize Psilocybin Treatment
Policy"Establishing a widespread route to provide New Yorkers with this medical treatment would be a monumental step in providing mental health care to improve lives,” reads the bill.
Compass Pathways Study Finds SSRI Drugs Did Not Impede Psilocybin’s Therapeutic Effect
ResearchChief Medical Officer Guy Goodwin calls study "a strong signal that COMP360 psilocybin therapy could be an adjunctive treatment to SSRI antidepressant as well as a monotherapy."
Microdosing LSD and Psilocybin Rises During Pandemic, Global Drug Survey Finds
Microdosing, ResearchThe report also explores how microdosing may impact the use of other prescribed mental health medications.
Psychedelic Business Spotlight: December 3
Business, Stock ReportsThis week in psychedelic business news: MAPS pioneers new funding structure; FDA green lights a Cybin study for Covid-19 distress; Compass Pathways gets new majority stakeholder.
DEA Boosts Psychedelics Production (Again) to Meet Research Demand
PolicyDrug Enforcement Agency also addresses concerns from Native American Church regarding peyote poaching for mescaline research.
Compass Pathways Releases Promising New Data from Landmark Psilocybin Therapy Trial
BusinessChief Medical Officer Dr. Guy Goodwin clarifies "COMP360 psilocybin therapy was generally well-tolerated" by patients with treatment-resistant depression, despite some adverse reactions from subjects in the study.